<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669487</url>
  </required_header>
  <id_info>
    <org_study_id>SEARCH003</org_study_id>
    <nct_id>NCT00669487</nct_id>
  </id_info>
  <brief_title>A 72-week Randomized Clinical Trial Comparing the Safety and Efficacy of Three Initial Antiretroviral Regimens -GPO-VIR S (d4T/3TC/NVP) for 24 Weeks Followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVP</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>South East Asia Research Collaboration with Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen Savang Vadhana Memorial Hospital, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thai Red Cross AIDS Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Hawaii</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>South East Asia Research Collaboration with Hawaii</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol aims to determine the risk/benefits of this policy by comparing head-to-head a
      regimen of GPO-VIR Z or TDF/FTC/NVP for 18 months in ARV-naïve patients to a 6-month lead in
      with GPO-VIR S followed by 12 months of GPO-VIR Z. The primary outcomes to be assessed will
      be anemia, neuropathy, lipoatrophy and renal function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GPO-VIR Z is a new combination antiretroviral (ARV) medication that substitutes zidovudine
      (AZT) for stavudine (d4T) from the original formulation of GPO-VIR S. This new combination
      should decrease rates of lipoatrophy and neuropathy which are side-effects strongly linked to
      the use of d4T. However, there is some risk that initiating therapy with an AZT- containing
      regimen may cause unacceptable rates of anemia. Many Thai physicians have adopted a practice
      of using 6 months of the stavudine-containing GPO-VIR S as a lead in before introducing
      AZT-containing GPO-VIR Z in an effort to balance the risks and benefits of these two
      medications. There are no definitive data, however, that can attest to the benefit of such an
      approach.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean hemoglobin at 24 weeks and 72 weeks</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with peripheral neuropathy at 24 weeks and 72 weeks</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in body weight, limb fat, and lean body mass by DEXA scan at 24 weeks and 72 weeks</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum creatinine at 24 weeks and 72 weeks</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with plasma HIV-1 RNA less than 50 copies/mL at 24 weeks and 72 weeks</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD4 count at 24 weeks and 72 weeks</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1. GPO-VIR S 1 pill orally every 12 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 GPO-VIR Z 1 pill orally every 12 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Truvada 1 pill oral q 24 hr and NVP 1 pill oral q 12 hr</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP</intervention_name>
    <description>Truvada(FTC200mg+TDF300mg) every 24 hours + NVP 200 mg every 12 hours orally until week 72</description>
    <arm_group_label>3 Truvada 1 pill oral q 24 hr and NVP 1 pill oral q 12 hr</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP</intervention_name>
    <description>GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z</description>
    <arm_group_label>1. GPO-VIR S 1 pill orally every 12 hours</arm_group_label>
    <arm_group_label>2 GPO-VIR Z 1 pill orally every 12 hours</arm_group_label>
    <arm_group_label>3 Truvada 1 pill oral q 24 hr and NVP 1 pill oral q 12 hr</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP</intervention_name>
    <description>GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72</description>
    <arm_group_label>1. GPO-VIR S 1 pill orally every 12 hours</arm_group_label>
    <arm_group_label>2 GPO-VIR Z 1 pill orally every 12 hours</arm_group_label>
    <arm_group_label>3 Truvada 1 pill oral q 24 hr and NVP 1 pill oral q 12 hr</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented HIV-1 infection

          2. Age ≥ 18 years old.

          3. Subjects must be naïve to ARV. Individuals with past exposure to ARV associated with
             pregnancy will be allowed to enroll as long as the exposure is at least 3 months prior
             to entry.

          4. CD4 &lt; 350 cells/mm3

          5. Subject understands the study and is able to sign informed consent

        Exclusion Criteria:

          1. Evidence of symptomatic persistent symptoms of tingling or numbness of lower
             extremities and bilateral lower extremity neuropathy on exam at entry. Abnormal exam
             includes 1) Diminished (compared with the knee) or absent ankle reflexes OR 2)
             Diminution of either vibration sensation in the legs (defined as perception of
             vibration for &lt; 10 seconds at the great toe with a tuning fork initially struck hard
             enough to be audible) OR 3) Diminution of pin or temperature sensation in lower
             extremities OR 4) Contact allodynia in the feet.

          2. Laboratory values 1) Absolute neutrophil count (ANC) &lt; 750/mm3 2) Hemoglobin &lt; 8.0
             g/dL 3) ALT (SGPT) &gt; 5 x ULN 4) Creatinine &gt; 2 X ULN or &lt; creatinine clearance &lt; 30 cc
             per min by Cockroft-Gault formula

          3. Active AIDS-defining opportunistic infection (OI) within 30 days prior to entry.
             Subjects must be off all acute treatments for OI for at least 14 days prior to entry.
             Subjects on maintenance or prophylactic therapy for AIDS-related OIs will be eligible.

          4. Any immunomodulator, HIV vaccine or investigational therapy within 30 days of study
             entry

          5. Pregnancy or breast-feeding; intent to become pregnant during the course of the study.

          6. Presence of any active malignancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jintanat - Ananworanich, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SEARCH Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jintanat - Ananworanich, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>SEARCH Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SEARCH Thailand</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2008</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South East Asia Research Collaboration with Hawaii</investigator_affiliation>
    <investigator_full_name>Assoc.Prof.Jintanat Ananworanich, M.D.</investigator_full_name>
    <investigator_title>Jintanat Ananworanich</investigator_title>
  </responsible_party>
  <keyword>HIV/AIDS patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Stavudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

